Description and In silico ADME Studies of US-FDA Approved Drugs or Drugs under Clinical Trial which Violate the Lipinski's Rule of 5
Background & Objective: Christopher A. Lipinski, in 1997, formulated Lipinski's rule of five for
drug-likeness prediction of potent molecules. It states that molecular weight (less than 500 …
drug-likeness prediction of potent molecules. It states that molecular weight (less than 500 …